Clinical trial · no report yet · Phase 2
STOPGAP
Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis
- NCT04762953 ↗
- Active not recruiting
- University of California, Irvine
- 17 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 8 | |
| Podcasts | 7 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase II Trial of Sequential Systemic Therapy Plus Intraperitoneal Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis (STOPGAP)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Gastric Cancer; Peritoneal Carcinomatosis; Gastroesophageal Junction Adenocarcinoma
- Interventions
- Paclitaxel; Paclitaxel; Leucovorin; Fluorouracil
- Arms
- SingleArm: Systemic therapy and IP Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis · Experimental
- Enrollment
- 40 (estimated)
- Primary outcomes
- Participants with Progression Free Survival at 1-Year
- Incidence of Treatment-Emergent Adverse Events [Safety]
- Sponsor
- University of California, Irvine
- Start
- Feb 18, 2021
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04762953 · updated Feb 3, 2026
Publications
linked from the registry- Senthil M, Dayyani F. Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial. BMC Cancer. 2023 Mar 4;23(1):209. doi: 10.1186/s12885-023-10680-1. PubMed 36870941